skip to main content
iatroX JournalExam revision

How to Pass the SCE Palliative Medicine Exam

Featured image for How to Pass the SCE Palliative Medicine Exam

The SCE Palliative Medicine is one of the smaller SCEs by candidate volume but one of the most clinically grounded. It tests symptom management at a pharmacological depth that goes well beyond what most general physicians encounter, combined with communication frameworks, ethical reasoning, and the management of non-malignant end-stage disease. The official Palliative Medicine page describes a nine-month cycle and lists the next sitting on 16 June 2027, with applications from 24 February to 24 March 2027. Use the published calendar rather than assuming a permanent annual June pattern.

What makes it challenging

The palliative medicine curriculum is pharmacology-heavy in a way that differs from other medical specialties. You must know opioid conversion ratios between morphine, oxycodone, fentanyl, alfentanil, hydromorphone, and methadone — including the non-linear conversion for methadone at higher doses. You must know syringe driver drug compatibility (which drugs can be mixed in the same syringe driver, which are incompatible, and which require specific diluents). You must know the pharmacology of anti-emetics in the palliative context — cyclizine, levomepromazine, haloperidol, ondansetron, metoclopramide — including their receptor profiles and the rationale for selection based on the cause of nausea.

The Federation resource list includes the Palliative Care Formulary alongside national and specialist guidance. Use product information and the relevant specialist guidance together when studying indications, off-label use, dosing, interactions and monitoring.

Topic weighting

Use the Palliative Medicine blueprint currently linked by the Federation to plan coverage. Its indicative total is 200 questions: other symptoms and clinical problems related to life-limiting disease have 48, pharmacology and therapeutics 35, and pain 15. Care of the dying patient, emergencies, palliation of life-limiting disease and concurrent problems unrelated to progressive illness each have 20. Legal issues have 15, practical procedures 5 and rehabilitation 2. Actual numbers can vary slightly; categories are distributed across both papers.

The document does not give the separate symptom-specific percentages previously listed here. Revise nausea, breathlessness, gastrointestinal and neurological symptoms, communication, non-malignant illness and prescribing within the full curriculum without treating them as fixed standalone allocations.

Opioid conversion

Practise opioid conversion as a calculation and clinical-assessment task, using the current formulary or guideline table specified for the scenario. Check the drug, formulation, route, total dose and patient factors before comparing equivalent doses. NHS Greater Glasgow and Clyde's prescribing guidance emphasises renal and hepatic function, toxicity, efficacy and incomplete cross-tolerance when changing opioids. Do not treat a memorised ratio as a complete switching prescription.

Use worked examples to check units and reasoning, then compare your answer with the named source. Complex switches, including methadone, need the relevant specialist guidance rather than a single universal conversion rule.

Revision strategy

One possible three-month plan starts with pharmacology, therapeutics and pain management while retaining the wider blueprint. Practise conversions against the relevant source and patient context rather than treating pain as the largest domain. Month two should cover nausea, respiratory symptoms, GI symptoms, and syringe driver prescribing. Month three should cover end-of-life care, communication ethics, non-malignant palliative care, and legal frameworks.

Use current product information, the PCF and applicable specialist guidance together, keeping the source and patient context explicit when comparing recommendations.

Use the iatroX SCE palliative medicine bank alongside the official blueprint and current guidance. £29/month or £99/year in the UK; US$29/month or US$99/year elsewhere

More from the Journal